![UMN logo](/assets/logo-14ca9c5bc764343ea0b1ec3edef3d39b15c438f8eb603b1a5fbf826128a74246.png)
StudyFinder
A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata
![](/assets/flag-998f631fa7bef54098575ae881e66e71315bfae4a5d1ffb34ab8f527fcff0600.jpg)
Recruiting
This study is being done to evaluate the safety and tolerability of twice daily application of the study drug, ARQ-255 topical suspension 3% people with alopecia areata. There are 2 study drugs in this study: ARQ-255 topical suspension 3% and vehicle (placebo). Participants will be randomized (like drawing straws) to either ARQ-255 topical suspension 3% or vehicle to be applied twice daily for 12 weeks. A vehicle is a study treatment that looks like the test drug and is made from the same base products used to make ARQ-255 topical suspension 3%, but it does not contain any active study ingredients.
Male or Female
18 years and over
Inclusion Criteria:
• 18 to 70 years of age
• have alopecia areata
• able to apply topical study medication
Exclusion Criteria:
• alopecia totalis
• alopecia universalis
Dermatology (Skin, Hair & Nails)
alopecia areata
Gretchen Bellefeuille - belle116@umn.edu
Maria Hordinsky
SITE00001818